173 related articles for article (PubMed ID: 18851761)
1. Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study.
Manosuthi W; Tantanathip P; Prasithisirikul W; Likanonsakul S; Sungkanuparph S
BMC Infect Dis; 2008 Oct; 8():136. PubMed ID: 18851761
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.
Anekthananon T; Ratanasuwan W; Techasathit W; Sonjai A; Suwanagool S
J Med Assoc Thai; 2004 Jul; 87(7):760-7. PubMed ID: 15521230
[TBL] [Abstract][Full Text] [Related]
4. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.
Bourgeois A; Laurent C; Mougnutou R; Nkoué N; Lactuock B; Ciaffi L; Liégeois F; Andrieux-Meyer I; Zekeng L; Calmy A; Mpoudi-Ngolé E; Delaporte E
Antivir Ther; 2005; 10(2):335-41. PubMed ID: 15865228
[TBL] [Abstract][Full Text] [Related]
5. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
[TBL] [Abstract][Full Text] [Related]
7. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.
Siegfried NL; Van Deventer PJ; Mahomed FA; Rutherford GW
Cochrane Database Syst Rev; 2006 Apr; 2006(2):CD004535. PubMed ID: 16625606
[TBL] [Abstract][Full Text] [Related]
8. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.
Getahun A; Tansuphasawadikul S; Desakorn V; Dhitavat J; Pitisuttithum P
J Med Assoc Thai; 2006 Sep; 89(9):1472-8. PubMed ID: 17100387
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
11. Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.
Idigbe EO; Adewole TA; Eisen G; Kanki P; Odunukwe NN; Onwujekwe DI; Audu RA; Araoyinbo ID; Onyewuche JI; Salu OB; Adedoyin JA; Musa AZ
J Acquir Immune Defic Syndr; 2005 Sep; 40(1):65-9. PubMed ID: 16123684
[TBL] [Abstract][Full Text] [Related]
12. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
Laurent C; Bourgeois A; Mpoudi-Ngolé E; Ciaffi L; Kouanfack C; Mougnutou R; Nkoué N; Calmy A; Koulla-Shiro S; Delaporte E
AIDS Res Hum Retroviruses; 2008 Mar; 24(3):393-9. PubMed ID: 18327976
[TBL] [Abstract][Full Text] [Related]
13. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.
Kumar PN; Rodriguez-French A; Thompson MA; Tashima KT; Averitt D; Wannamaker PG; Williams VC; Shaefer MS; Pakes GE; Pappa KA;
HIV Med; 2006 Mar; 7(2):85-98. PubMed ID: 16420253
[TBL] [Abstract][Full Text] [Related]
14. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.
van Oosterhout JJ; Kumwenda JJ; Beadsworth M; Mateyu G; Longwe T; Burger DM; Zijlstra EE
Antivir Ther; 2007; 12(4):515-21. PubMed ID: 17668560
[TBL] [Abstract][Full Text] [Related]
15. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
Tam LW; Hogg RS; Yip B; Montaner JS; Harrigan PR; Brumme CJ
HIV Med; 2007 Jul; 8(5):267-70. PubMed ID: 17561871
[TBL] [Abstract][Full Text] [Related]
16. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults.
Raffi F; Reliquet V; Ferré V; Arvieux C; Hascoet C; Bellein V; Besnier JM; Breux JP; Garré M; May T; Molina JM; Perré P; Raguin G; Rozenbaum W; Zucman D
Antivir Ther; 2000 Dec; 5(4):267-72. PubMed ID: 11142621
[TBL] [Abstract][Full Text] [Related]
17. Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients.
Manosuthi W; Kiertiburanakul S; Chaovavanich A; Sungkanuparph S
J Med Assoc Thai; 2007 Feb; 90(2):244-50. PubMed ID: 17375627
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection.
Katlama C; Valantin MA; Matheron S; Coutellier A; Calvez V; Descamps D; Longuet C; Bonmarchand M; Tubiana R; De Sa M; Lancar R; Agut H; Brun-Vezinet F; Costagliola D
Ann Intern Med; 1998 Oct; 129(7):525-31. PubMed ID: 9758571
[TBL] [Abstract][Full Text] [Related]
19. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
Reliquet V; Ferré V; Hascoet C; Besnier JM; Bellein V; Arvieux C; Molina JM; Breux JP; Zucman D; Rozenbaum W; Allavena C; Raffi F;
Antivir Ther; 1999; 4 Suppl 3():83-4. PubMed ID: 16021876
[TBL] [Abstract][Full Text] [Related]
20. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]